Withaferin A Regulates LRRK2 Levels by Interfering with the Hsp90- Cdc37 Chaperone Complex.

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Leucine-Rich Repeat Kinase 2 (LRRK2) mutations are linked to Parkinson's, Alzheimer's, and Crohn's disease.
• Increased LRRK2 levels contribute to neuronal toxicity, necessitating methods to reduce its expression.
• Heat shock protein 90 (Hsp90) and its co-chaperone Cdc37 stabilize LRRK2.

Purpose of the Study:

• To investigate the regulation of LRRK2 by withaferin A (WA), an inhibitor of the Hsp90-Cdc37 interaction.
• To explore the potential of targeting the Hsp90-Cdc37 complex for controlling LRRK2 levels.

Main Methods:

• Treatment of N9 microglial cells with withaferin A (WA) and celastrol.
• Assessment of LRRK2 protein levels via dose- and time-dependent studies.
• Analysis of the interaction between Hsp90, Cdc37, and LRRK2.

Main Results:

• Withaferin A (WA) treatment dose- and time-dependently decreased cellular LRRK2 levels.
• WA disrupted the Hsp90-Cdc37-LRRK2 complex, leading to LRRK2 destabilization and reduction.
• Celastrol also decreased LRRK2 levels, and combined treatment with WA enhanced LRRK2 clearance.

Conclusions:

• LRRK2 levels can be effectively regulated by targeting the Hsp90-Cdc37 chaperone complex.
• Inhibiting the Hsp90-Cdc37 interaction presents a promising therapeutic avenue for LRRK2-associated neurodegenerative diseases.
• This study provides a foundation for developing novel pharmacological strategies for Parkinson's, Alzheimer's, and other LRRK2 proteinopathies.